Research Interests
My current research focuses on uterine fibroids. These non-cancerous, often bulky and firm tumors have a major impact on women’s health, on quality of life and on health cost. They are a leading cause for hysterectomies and Black women are affected more severely and at a younger age. Medical treatment options mostly target hormone levels and are either short-lived or have significant side effects. The etiology of this disease remains poorly understood. Our research embraces a new direction in thinking about uterine fibroids. Uterine fibroids are more than neoplasms; they are a fibrotic disease. Abundant extracellular matrix (ECM) is a major component of uterine fibroid tumors and we focus on the production and degradation of collagen within the fibroids, changing the mechanical forces within these tumors leading to changes in stiffness. We are currently testing the local injection of purified collagenase into uterine fibroids. This treatment option can be carried out under ultrasound control, is non-hormonal, and does not require surgery. I also collaborate with Dr. Darlene Taylor at North Carolina Central University (NCCU). She is a chemist who developed a co-polymer drug delivery system that is liquid at room temperature and gels at body temperature. Collagenase (or other anti-fibrotic drugs) injected into fibroids in combination with her co-polymer could extend the localization and activity of the drugs within the treated tumors, allow for lower dosages, and reduce the need for repeat injections.
Selected Grants
1/3 CTSA UM1 at Duke University
ResearchFaculty Member · Awarded by National Institutes of Health · 2025 - 2032Duke Women's Reproductive Health Research Scholars
Inst. Training Prgm or CMEProgram Coordinator · Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development · 2020 - 2030Duke KURe Program
Inst. Training Prgm or CMEProgram Coordinator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2013 - 2028Building Interdisciplinary Research Careers in Women's Health - BIRCWH
Inst. Training Prgm or CMEProgram Assistant · Awarded by National Institute of Arthritis and Musculoskeletal and Skin Diseases · 2002 - 2027Evaluating the Safety of Smart Injectable Drug Delivery for Uterine Fibroid Therapy
ResearchPrincipal Investigator · Awarded by North Carolina Central University · 2021 - 2023Fellowships, Gifts, and Supported Research
Duke-NCCU Collaborative Translational Research Pilot Supplemental Award (2025) ·
January 2, 2025
- June 30, 2025
Co-Principal Investigator ·
Awarded by: Duke-NCCU Bridge Office and Duke Clinical and Translational Science Institute (CTSI)
· $40,000.00
Injectable Drug Delivery for Uterine Fibroids II: Drug, Quadpolymer, and Formulation
Studies
Sponsored by the Duke-NCCU Bridge Office and Duke Clinical and Translational Science Institute (CTSI) and administered by the CTSI Accelerator, this targeted funding aims to capitalize on promising opportunities that emerged from previously funded Duke-NCCU collaborations between 2018 and 2023. In addition to funding, the awarded teams will receive project management support from CTSI project leaders.
The team pairs reproductive physiologist Friederike Jayes, DVM, PhD, from Duke with chemist Darlene Taylor, PhD, from NCCU to tackle a prevalent women's health issue. They are developing a novel, minimally invasive treatment for uterine fibroids as an alternative to surgery. Their technology is based on delivering a highly purified enzyme (collagenase) using a breakthrough injectable hydrogel-copolymer called LiquoGelâ„¢ that allows delivery of a high drug payload.
Developing a new treatment for uterine fibroids - local injection of purified Clostridial collagenase ·
January 1, 2025
- December 31, 2025
Co-Principal Investigator ·
Awarded by: The Charles Hammond Research Fund
· $12,500.00
Expanding on the proposed research from 2024, we will continue our research leading to the development of a non-hormonal, uterine preserving treatment for uterine fibroids.
Collagen is the major component in these stiff and often bulky uterine fibroids. Local injection of fibroids with a highly purified collagenase (from Clostridium Histolyticum) will degrade the collagen and considerably soften fibrotic tissues.
Developing a new treatment for uterine fibroids - local injection of purified Clostridial collagenase ·
February 2024
- January 2025
PI ·
Awarded by: The Charles Hammond Research Fund Award
· $12,000.00
The only definitive treatment for uterine fibroids is hysterectomy. Exiting uterine preserving procedures involve major equipment, high cost, and specialized expertise and are not offered or not accessible to many women. Systemic delivery of drugs, including hormonal, has been problematic due to systemic side effects. There is a clear need for new treatment options that are uterine preserving, minimal invasive, and accessible to women in all communities.
We have collaborated to develop such a new treatment. Collagen is the major component in these stiff and often bulky uterine fibroids. We have shown in ex-vivo experiments, that injection of fibroids with a highly purified collagenase (from Clostridium Histolyticum) will degrade the collagen and considerably soften fibrotic tissues. A phase-1 clinical trial proved that local delivery under ultrasound guidance using IVF needles is feasible, and in addition to softening the fibroid tissue, it could also lead to a reduction in pain
Engineering Smart Injectable Drug Delivery Theranostics for Uterine Fibroids ·
January 1, 2019
- December 31, 2019
Co-Principal Investigator ·
Awarded by: Duke Clinical and Translational Science Institute (CTSI)
· $56,131.00
Friederike Jayes, DVM, PhD, and Darlene K. Taylor, PhD have been awarded a Duke-NCCU collaborative award for 2019. The research award will advance studies to deliver drugs via LiquoGelâ„¢ to potentially soften and treat uterine fibroid tumors. More than seven out of ten women have fibroids by age 50. The disease burden is larger for black women as they have more fibroids earlier in life when many still desire to have children. The targeted technology could transform uterine fibroid therapy for women suffering from this disease who want to keep their uterus.